The MHRA set out on 13 January 2026, the next phase of reforms aimed at strengthening the clinical trial landscape in the UK. These reforms come at a time of renewed momentum for clinical research.
The National Institute for Care and Excellence (NICE) announced on 16 December 2025 that Professor Jonathan Benger CBE will be the organisation’s next Chief Executive, from Friday 19 December 2025. Professor Benger replaces Dr Samantha Jones, who has held the post since 2021.
In November 2025, Parkinson’s disease stood out as one of the most frequently mentioned conditions examined by UK Parliamentarians and was mentioned nearly three times more often in November than its usual monthly average.
The UK Government announced on 1 December 2025 a landmark deal that is expected to benefit NHS patients by expanding access to vital medicines, strengthening the UK’s pharmaceutical supply chain, and attracting new investment into the country’s life sciences sector.
The MHRA published on 2 November 2025, a Policy Paper outlining the Agency’s intentions to improve regulatory pathways for rare disease therapies to be tested, manufactured and approved in the UK.
The NHS announced on 17 October 2025 that it would roll out a new long-acting injection to prevent HIV, as part of its ambition to become the first country in the world to end HIV transmissions by 2030.
